Patients eligible for transplant

New imaging methodology enables rapid assessment of transplant success in…

New imaging methodology enables rapid assessment of transplant success in hematologic malignancies

General MM

The concept of a cure in MM: a comparison of survival outcomes

Patients eligible for transplant

Validation of the R-ISS for stratification of transplant-eligible MM…

General MM

Detection of MM-associated translocations and mutations in IGLL5

Detection of MM-associated translocations and mutations in IGLL5

General MM

Treatment to suppression of focal lesions in NDMM is an important…

General MM

High BMI in early and late adulthood is a risk factor for MM

Relapsed/refractory patients

Response kinetics and treatment outcomes in RRMM

Response kinetics and treatment outcomes in RRMM

Patients eligible for transplant

EBMT 2018 | Pre-transplant Induction in MM

Elderly patients

EMBT 2018 | Therapies for fit, elderly MM patients

General MM, Patients eligible for transplant, Patients non-eligible for transplant, & 1 more

Following NICE guidelines | An interview with Ceri Bygrave

Following NICE guidelines | An interview with Ceri Bygrave

Patients eligible for transplant

EBMT 2018 | Galinpepimut-S (GPS) vaccine in high-risk MM

Patients eligible for transplant

EBMT 2018 | Efficacy and safety of bortezomib in allogeneic-transplant for…

Prof. Mohamad Mohty | EBMT 2018 | Role of double auto-transplant in…

Prof. Mohamad Mohty | EBMT 2018 | Role of double auto-transplant in Multiple Myeloma

General MM

EBMT 2018 | Cost-effectiveness of modern MM therapies

General MM

EBMT 2018 | CD229 is a promising target for MM

A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Latest Expert Opinions

General MM,Patients eligible for transplant,Patients non-eligible for transplant,Relapsed/refractory patients

Following NICE guidelines | An interview with Ceri Bygrave

Mar 29, 2018

Prof. Mohamad Mohty | EBMT 2018 | Role of double auto-transplant in Multiple Myeloma

Mar 22, 2018

English & Spanish

General MM

Prof. Joan Bladé | EBMT 2018 | Optimal induction in the transplant setting

Mar 19, 2018

Latest Biology

General MM

Detection of MM-associated translocations and mutations in IGLL5

Apr 17, 2018

General MM

Daratumumab enhances NK cell cytotoxicity

Mar 19, 2018

General MM

MM-induced bone disease: an overview and updated guidelines

Jan 28, 2018

Latest Drug Updates

Relapsed/refractory patients

Selinexor receives FDA fast track designation

Apr 13, 2018

General MM,Relapsed/refractory patients,Patients eligible for transplant

Denosumab approved for MM in Europe

Apr 11, 2018

Patients non-eligible for transplant

REVLIMID (lenalidomide) approved in China for treatment of transplant-ineligible MM…

Mar 7, 2018

Where we are next

The 4th World Congress on CONTROVERSIES IN MULTIPLE MYELOMA (COMy)

May 3-5, 2018 | Paris, France

The Multiple Myeloma Hub will be attending the 2018 Controversies in Multiple Myeloma meeting in Paris from 3-5 May 2018. Some of the biggest names in Multiple Myeloma will gather together to discuss the latest advances in treatment and guidelines for disease management, in the form of talks, case studies, and active debate. Stay tuned to the MM Hub to follow for our first-hand coverage.

Event Website

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology

Professional society

The European School of Haematology (ESH) is a not-for-profit institution for continuing education founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH Conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in Haematology.

Our partners

Supporter information coming soon